1. Incidence and Impact of Takotsubo Syndrome in Hospitalized Patients With COVID-19
- Author
-
Pengyang Li, MD, MSc, Ao Shi, PhD, Xiaojia Lu, MD, Chenlin Li, MD, Peng Cai, MSc, Catherine Teng, MD, Lingling Wu, MD, Yuan Shu, Su Pan, MD, Richard A. F. Dixon, PhD, Qi Liu, PhD, and Bin Wang, MD, PhD
- Subjects
covid-19 ,takotsubo cardiomyopathy ,mortality ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Takotsubo syndrome has been reported in patients with COVID-19, although minimal data are available. This investigation assessed the incidence and impact of takotsubo syndrome on patients hospitalized with COVID-19. Methods A retrospective cohort study was conducted using International Statistical Classification of Diseases, Tenth Revision, codes to identify patients with a primary diagnosis of COVID-19 with or without takotsubo syndrome in the National Inpatient Sample 2020 database. Outcomes between groups were compared after propensity score matching for patient and hospital demographics and comorbidities. Results A total of 211,448 patients with a primary diagnosis of COVID-19 were identified. Of these, 171 (0.08%) had a secondary diagnosis of takotsubo syndrome. Before matching, patients with COVID-19 and takotsubo syndrome, compared with patients without takotsubo syndrome, were older (68.95 vs 64.26 years; P < .001); more likely to be female (64.3% vs 47.2%; P < .001); and more likely to have anxiety (24.6% vs 12.8%; P < .001), depression (17.5% vs 11.4%; P = .02), and chronic obstructive pulmonary disease (24.6% vs 14.7%; P < .001). The takotsubo syndrome group had worse outcomes than the non–takotsubo syndrome group for death (30.4% vs 11.1%), cardiac arrest (7.6% vs 2.1%), cardiogenic shock (12.9% vs 0.4%), length of hospital stay (10.7 vs 7.5 days), and total charges ($152,685 vs $78,468) (all P < .001). After matching and compared with the non–takotsubo syndrome group (n = 508), the takotsubo syndrome group (n = 170) had a higher incidence of inpatient mortality (30% vs 14%; P < .001), cardiac arrest (7.6% vs 2.8%; P = .009), and cardiogenic shock (12.4% vs 0.4%; P < .001); a longer hospital stay (10.7 vs 7.6 days; P < .001); and higher total charges ($152,943 vs $79,523; P < .001). Conclusion Takotsubo syndrome is a rare but severe in-hospital complication in patients with COVID-19.
- Published
- 2024
- Full Text
- View/download PDF